NASDAQ:AXSM

Axsome Therapeutics Stock News

Healthcare > Biotechnology

Buy AXSM

*Your capital is at risk

$233.49

+11.33 (+5.10%)

At Close: Jun 03, 2026

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

07:00am, Thursday, 06'th Nov 2025

Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABA A α2,3 receptor positive allosteric modulator

Axsome: Alzheimer's Disease Agitation sNDA Adds Optionality, Not A Thesis Changer

03:12pm, Wednesday, 05'th Nov 2025

Axsome Therapeutics remains a 'Sell' due to an undifferentiated CNS pipeline, heavy SG&A, and ongoing net losses despite revenue growth. Auvelity's sales growth appears largely marketing-driven and co

AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales

11:30am, Tuesday, 04'th Nov 2025

Axsome incurs wider-than-expected Q3 loss but revenues soar 63% on booming Auvelity sales, with Sunosi and the newest drug, Symbravo, aiding the top line.

Axsome Therapeutics, Inc. (AXSM) Q3 2025 Earnings Call Transcript

02:46pm, Monday, 03'rd Nov 2025

Axsome Therapeutics, Inc. ( AXSM ) Q3 2025 Earnings Call November 3, 2025 8:00 AM EST Company Participants Darren Opland - Director of Corporate Communications Herriot Tabuteau - Founder, Chairman, CE

Axsome Therapeutics (AXSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

11:00am, Monday, 27'th Oct 2025

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

11:20am, Friday, 24'th Oct 2025

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) breached their fiduciary d

Axsome Therapeutics' Strong Growth And Expanding Pipeline: Why I Assign A Buy Rating

04:07am, Friday, 10'th Oct 2025

Axsome Therapeutics is transitioning into a leading neuroscience company with three marketed drugs and a robust late-stage pipeline. Q2 2025 saw 72% YoY revenue growth, driven by Auvelity and Sunosi,

Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community

07:00am, Thursday, 09'th Oct 2025

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an

Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3

07:00am, Tuesday, 07'th Oct 2025

NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an

Can Auvelity Drive Axsome's Growth Through the Rest of 2025?

10:46am, Tuesday, 30'th Sep 2025

AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.

Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years

04:10am, Tuesday, 30'th Sep 2025

Every investor wants to outperform the market, but it's a challenging feat to achieve. That's why few manage to do it consistently over long periods.

Axsome Therapeutics, Inc. (AXSM) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript

01:53am, Thursday, 18'th Sep 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM ) TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit September 17, 2025 8:40 AM EDT Company Participants Mark Jacobson - Chief Operating

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by